Olaparib (DrugBank: Olaparib)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
86 | Pulmonary arterial hypertension | 2 |
285 | Fanconi anemia | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03782818 (ClinicalTrials.gov) | November 20, 2019 | 17/12/2018 | Olaparib for PAH: a Multicenter Clinical Trial | Olaparib for Pulmonary Arterial Hypertension: a Multicenter Clinical Trial | Pulmonary Arterial Hypertension | Drug: Olaparib | Laval University | Canadian Institutes of Health Research (CIHR);AstraZeneca | Recruiting | 18 Years | 75 Years | All | 20 | Phase 1;Phase 2 | Canada |
2 | NCT03251872 (ClinicalTrials.gov) | October 25, 2018 | 13/8/2017 | Olaparib for PAH: a Pilot Study | Olaparib for Pulmonary Arterial Hypertension: a Pilot Clinical Study | Pulmonary Arterial Hypertension | Drug: Olaparib | Laval University | NULL | Terminated | 18 Years | 75 Years | All | 6 | Early Phase 1 | Canada |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04483544 (ClinicalTrials.gov) | August 10, 2020 | 20/7/2020 | Pembrolizumab and Olaparib in Cervical Cancer Patients | Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair Pathway | Cervical Cancer;Cervical Carcinoma | Drug: pembrolizumab;Drug: olaparib | Baptist Health South Florida | Florida Department of Health;Merck Sharp & Dohme Corp. | Recruiting | 18 Years | N/A | Female | 48 | Phase 2 | United States |
2 | NCT04042831 (ClinicalTrials.gov) | June 9, 2020 | 29/7/2019 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | A Phase II Study of Olaparib in Patients With Advanced Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | ARID1A Gene Mutation;ATM Gene Mutation;ATR Gene Mutation;Bile Duct Adenocarcinoma;BRCA1 Gene Mutation;BRCA2 Gene Mutation;BRIP1 Gene Mutation;CHEK2 Gene Mutation;EMSY Gene Mutation;Fanconi Anemia Complementation Group Gene Mutation;Metastatic Bile Duct Carcinoma;MRE11 Gene Mutation;NBN Gene Mutation;PALB2 Gene Mutation;PTEN Gene Deletion;RAD51 Gene Mutation | Drug: Olaparib | Academic and Community Cancer Research United | National Cancer Institute (NCI) | Recruiting | 18 Years | N/A | All | 36 | Phase 2 | United States |